Event info

Date:	28 May
Time:	8.30
Venue:	Medicon Valley Alliance, Copenhagen

Contact person

EXTERNAL EVENT

Michael Linnell
michael.linnell@nordiskemedier.se

New Horizons in Biologics & Bioprocessing

This international educational forum has an emphasis on new directions, R&D and improvements of biologics, bioprocessing and ATMP with a focus on technical, rather than commercial, achievements. Topics may include analytical techniques, cell culturing and upstream processing, downstream processing, single-use systems, gene-therapy and regulatory issues.

The event is mainly aimed at the following target audience:

Biotech companies – all – start up, small-medium sized, large
Researchers from academia and industry
Large Pharma with interest in biotech
Contract manufacturing organisations
Engineering houses and consultants
QA Managers
Process developers
Process engineers
Manufacturing and production managers
Procurement groups
Investment Managers

As a registered participant, you will have the opportunity to browse all attendees (including partners and exhibitors) and request one-to-one meetings on-site using our online partnering platform, Meeting Mojo. Login details and instructions will be distributed to all registered participants, starting 2 weeks before the event date.

Date: 28 May, 2024
Time: 9.00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 13, Copenhagen

Click here to read more and sign up.

Programme

Note that changes to the programme may occur. For the most updated program check this page before the event.

08.00	Registration, 1-2-1 meetings & networking in the exhibition hall
08.30	Welcome and introduction Morten Munk, Director Global Alliance Management, FUJIFILM Diosynth Biotechnologies
08.35	Gene therapy: Cure for the patient – curse for the manufacturer? Johan Rockberg, Professor in Antibody Technology and Directed Evolution, KTH Royal Institute of Technology
09.00	Breaking down cell therapy manufacturing hurdles: GMP solutions as game-changers Anil Kumar, PhD, Head of CMC in Europe, ACROBiosystems
09.25	Medicine of the future Cecilia Norling, MSc in Medical Biology, Quality Assurance Manager, VERIGRAFT
09.50	How to really accelerate medicines to patients? Mark Walsh, Commercial Director, APC & VLE
10.00	Accelerating the delivery of life changing onclytic medicines to patients Stephen Craven, Director, Large Molecule Business Unit, APC & VLE
10.15	Coffee, 1-2-1 meetings & networking in the exhibition hall
10.45	A highly efficacious vaccine against malaria – why is it so difficult? Kristina Persson, Associate Professor, Senior Lecturer, Lund University, and Senior Consultant, Laboratory Medicine, Lund University Hospital
11.10	Preclinical proof of concept for a novel VLP-based vaccine candidate for treatment of HER2+ breast cancer Max Søgaard, Senior VP R&D and Technology, ExpreS2ion Biotechnologies
11.35	Xbrane and the development of high quality biosimilars David Vikström, Chief Technology Officer, Xbrane Biopharma
12.00	Lunch, 1-2-1 meetings & networking in the exhibition hall
13.00	From science to cutting edge technology: Supporting pharmaceutical innovations in the Nordic biotech Christian Clausen, CSO, Bioneer
13.25	A novel in-line sensor system for real-time bioprocess monitoring Erik Martinsson, CEO and Co-founder, ArgusEye
13.50	New Annex 1- requirements on fill and finish machines Matthias Mikkelsen, Subject Matter Expert, Watson Marlow Flexicon
14.15	Fermentation harvest modalities using single use centrifuges Peter Thorwid, Concepts Manager, Business Unit High Speed Separators, Alfa Laval Pontus Linderholm, R&D Manager Single-Use, Business Unit High Speed Separators, Alfa Laval
14.40	Coffee, 1-2-1 meetings & networking in the exhibition hall
15.15	Cellevat3d™microcarriers – The 1st nanofiber-based microcarriers designed for viral vector biomanufacturing Laura Chirica, PhD, CEO, Cellevate
15.40	Is our industry really industrialised? – Industrialising biologics to dramatically improve patient access with the modular kojoX approach Rasmus Pedersen, Senior Modularity Architect, FUJIFILM Diosynth Biotechnologies
16.05	Boosting the speed of Genmab’s CMC timelines for antibody products Jesper Valbjørn, Senior Vice President, Head of Global CMC Operations, Genmab
16.30 ~16.35	Summary & conclusion Morten Munk, Director Global Alliance Management, FUJIFILM Diosynth Biotechnologies

Speakers

	Morten Munk Director, Global Alliance Management FUJIFILM Diosynth Biotechnologies
	Johan Rockberg Professor in Antibody Technology and Directed Evolution KTH Royal Institute of Technology
	Cecilia Norling MSc in Medical Biology Quality Assurance Manager, VERIGRAFT
	Stephen Craven Director, Large Molecule Business Unit APC & VLE
	Mark Walsh Commercial Director APC & VLE
	Kristina Persson Associate Professor, Senior Lecturer, Lund University Senior Consultant, Laboratory Medicine, Lund University Hospital
	Max Søgaard Senior VP R&D and Technology ExpreS2ion Biotechnologies
	David Vikström Chief Technology Officer Xbrane Biopharma
	Christian Clausen CSO Bioneer
	Erik Martinsson CEO and Co-founder ArgusEye
	Peter Thorwid Concepts Manager, Business Unit High Speed Separators Alfa Laval
	Pontus Linderholm R&D Manager Single-Use, Business Unit High Speed Separators Alfa Laval
	Laura Chirica PhD, CEO Cellevate
	Rasmus Pedersen Senior Modularity Architect FUJIFILM Diosynth Biotechnologies
	Jesper Valbjørn Senior Vice President, Head of Global CMC Operations Genmab
	Anil Kumar PhD, Head of CMC in Europe ACROBiosystems
	Matthias Mikkelsen Subject Matter Expert Watson Marlow Flexicon